7. Celldex Therapeutics, I., Data Safety and Monitoring Board Recommends Celldex's Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease. 2016, Acquire Media: http://www.globenewswire.com/Tracker?data=_TmMCPhs6za4YEb90JOnEl4AANra7qs AR-AXlXI1axmp1el3q6YpAV6uHW3N_DYQn4NajzZWEBGY6a7DKkY8Cw==.